
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Anavex Life Sciences Corp (AVXL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AVXL (5-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $34.33
1 Year Target Price $34.33
2 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.63% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 828.02M USD | Price to earnings Ratio - | 1Y Target Price 34.33 |
Price to earnings Ratio - | 1Y Target Price 34.33 | ||
Volume (30-day avg) 3 | Beta 0.8 | 52 Weeks Range 4.93 - 14.44 | Updated Date 08/29/2025 |
52 Weeks Range 4.93 - 14.44 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.1457 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.41% | Return on Equity (TTM) -43.64% |
Valuation
Trailing PE - | Forward PE 3.89 | Enterprise Value 690777149 | Price to Sales(TTM) - |
Enterprise Value 690777149 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -5.54 | Shares Outstanding 85893800 | Shares Floating 83048171 |
Shares Outstanding 85893800 | Shares Floating 83048171 | ||
Percent Insiders 3.31 | Percent Institutions 38.32 |
Upturn AI SWOT
Anavex Life Sciences Corp

Company Overview
History and Background
Anavex Life Sciences Corp. was founded in 2004. It is a biopharmaceutical company focused on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) disorders.
Core Business Areas
- Drug Development: Research and development of novel drug candidates targeting neurodegenerative and neurodevelopmental diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
- Commercialization: Seeking regulatory approval and commercializing approved products.
Leadership and Structure
Christopher U Missling, PhD (President and CEO). The company operates with a research and development-focused organizational structure, with departments dedicated to preclinical research, clinical development, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- ANAVEXu00ae2-73 (blarcamesine): An investigational drug candidate for the treatment of Alzheimer's disease, Parkinson's disease, Rett syndrome, and other CNS disorders. Currently in clinical trials. Market share is pending regulatory approval and commercialization. Competitors include companies developing Alzheimer's and Parkinson's disease therapeutics, such as Biogen (BIIB), Eli Lilly (LLY), and Roche (RHHBY).
- ANAVEXu00ae3-71: An investigational drug candidate for the treatment of neurodegenerative diseases. Currently in preclinical and early clinical development. Market share is pending regulatory approval and commercialization. Competitors include companies developing Alzheimer's therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is highly competitive and rapidly evolving, with a significant unmet need for effective treatments.
Positioning
Anavex Life Sciences Corp. is a smaller player in the pharmaceutical market, primarily focused on the sigma-1 receptor, and is developing drug candidates with potential disease-modifying effects. This is a more novel and risky approach as opposed to the symptomatic treatments that the big players focus on.
Total Addressable Market (TAM)
The TAM for Alzheimer's and Parkinson's disease therapeutics is estimated to be tens of billions of dollars annually. Anavex is positioned to potentially capture a share of this market if its drug candidates are approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential disease-modifying effects
- Strong intellectual property portfolio
- Experienced management team
- Sigma-1 receptor focus which other companies are not focusing on
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
- Dependence on successful development and commercialization of drug candidates
- Small team
Opportunities
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion of pipeline through acquisition or in-licensing of new drug candidates
- Regulatory approval and commercialization of drug candidates
- Breakthrough Therapy designation from FDA
Threats
- Clinical trial failures
- Competition from other companies developing treatments for neurodegenerative diseases
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- RHHBY
- ABBV
Competitive Landscape
Anavex is smaller than its main competitors. ANAVEXu00ae2-73 offers a unique mechanism and may be superior in the long term if proven through data during clinical trials and is able to navigate regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by advancements in clinical trials and securing financing.
Future Projections: Future growth is contingent on the successful completion of clinical trials and regulatory approval of drug candidates. Analyst estimates are highly variable and depend on trial outcomes.
Recent Initiatives: Advancing clinical trials for ANAVEXu00ae2-73 in Alzheimer's disease, Parkinson's disease, and Rett syndrome. Exploring new indications for drug candidates.
Summary
Anavex Life Sciences Corp. is a high-risk, high-reward biopharmaceutical company. While the company's novel approach offers significant potential, it faces challenges related to funding, clinical trial success, and regulatory approval. Positive clinical trial outcomes for ANAVEXu00ae2-73 could lead to substantial value creation, but negative results could significantly impact the company's prospects. They need to secure more funding and continue to push for regulatory approval. The success of trials and regulatory approval are the main aspects to look out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Press releases
- Analyst reports
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investing in biopharmaceutical companies carries significant risk. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anavex Life Sciences Corp
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-08-02 | President, CEO, Secretary & Director Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 42 | Website https://www.anavex.com |
Full time employees 42 | Website https://www.anavex.com |
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.